SCHEDULE: Heron Therapeutics Secures $66M Funding, Adds Investor to Board

Heron Therapeutics has entered into a series of agreements, including a $66.38 million capital raise through common stock, preferred stock, and convertible notes, alongside a governance agreement granting a board seat to Rubric Capital Management LP.

Summary

• Heron Therapeutics, Inc. (the Company) and Rubric Capital Management LP (the Investor) entered into a Cooperation Agreement, Securities Purchase Agreement, and Note Purchase Agreement, all dated August 8, 2025, with closings on August 12, 2025.
• The Company raised approximately $66.38 million in gross proceeds from Rubric Funds through a private placement and convertible note issuance.
• The private placement involved the sale of 2,387,225 shares of common stock at $1.50 per share and 94,610 shares of Series A Convertible Preferred Stock (Preferred Stock) at $1.50 per share, which convert into 946,100 common shares upon stockholder approval.
• The convertible note issuance involved $35,000,000 aggregate principal amount of convertible senior unsecured promissory notes (Notes) for an aggregate purchase price of $33,250,000 (a 5% original issuance discount).
• The Notes bear cash interest at 5.0% per annum, payable semi-annually, with an option for the Company to pay interest in new Notes at 7.0% per annum for the first 12 months (prior to September 1, 2026). The Notes mature on March 1, 2031.
• Rubric Capital Management LP and David Rosen beneficially own 29,100,728 shares of common stock, representing 17.5% of the outstanding class.
• The Cooperation Agreement fixes the Board of Directors' size at seven directors and provides for the appointment of an Investor-nominated director (Investor Appointee) to the Board, who will receive the same compensation and benefits as other non-management directors.
• The Investor agrees to vote its shares in favor of the Board's recommended slate of directors and against unapproved nominees, with certain exceptions for ISS/Glass Lewis recommendations and Extraordinary Transactions.
• The Investor is subject to a standstill provision, limiting its beneficial ownership to 19.99% of outstanding voting securities and restricting certain activist actions until February 12, 2026, or earlier based on specific conditions.
• The Company will seek stockholder approval for the conversion of the Preferred Stock and Notes into common stock and will file a preliminary proxy statement within 30 days of closing.
• The Company will file a resale registration statement for the shares issued or issuable within 30 days of closing, with penalties for delays in filing or effectiveness.

Sentiment

Score: 7

Explanation: The filing indicates a successful capital raise and strategic partnership with a significant investor, addressing funding needs and potentially strengthening governance. While there is dilution and new debt, these are common for development-stage biotech companies and are managed through structured agreements. The overall sentiment is positive due to enhanced financial stability and strategic alignment, despite inherent industry risks.

Positives

• Secured significant capital raise of approximately $66.38 million, strengthening the Company's financial position.
• Established a cooperation agreement with a major investor, Rubric Capital Management LP, which includes board representation, potentially enhancing corporate governance and strategic alignment.
• The capital raise includes a convertible note component, providing flexible financing with an initial 5% cash interest rate.
• The Company is undertaking a debt restructuring by entering an exchange agreement to repurchase/convert $150,000,000 of 1.5% senior convertible notes due 2026, which could improve the debt maturity profile.
• The Company is amending its working capital facility with Hercules Capital, Inc. to an aggregate principal amount of $110,000,000, indicating continued access to credit.
• Commitment to preserve Net Operating Losses (NOLs) in accordance with IRC Section 382, which could provide future tax benefits.

Negatives

• The capital raise involves significant dilution for existing common stockholders through the issuance of new common stock, preferred stock convertible into common stock, and convertible notes.
• The convertible notes add $35,000,000 in new debt to the Company's balance sheet, incurring interest payment obligations.
• The 5% original issuance discount on the convertible notes means the Company received $33,250,000 for $35,000,000 principal amount, effectively increasing the cost of capital.
• The Company is a development-stage business with limited operating history, indicating inherent business risks and a continued need for substantial funds.
• The investment is speculative, with the potential for complete loss of investment for purchasers.
• Transferability of the newly issued securities is initially limited due to registration requirements and restrictive legends.

Risks

• The Company remains a development stage business with limited operating history and requires substantial funds in addition to the proceeds from the sale of the Securities.
• An investment in the Company is speculative, and only Purchasers who can afford the loss of their entire investment should consider investing in the Company and the Securities.
• Transferability of the Securities is extremely limited.
• The Company has not paid any dividends on its Common Stock since inception and does not anticipate the payment of dividends in the foreseeable future.
• Potential for delisting or suspension of Common Stock trading if the Company falls below minimum listing maintenance requirements of its exchange.
• Failure to obtain stockholder approval for the conversion of the Preferred Stock and Notes into Common Stock could limit the Company's ability to issue shares.
• Failure to timely file or maintain effectiveness of the resale registration statement could result in significant Registration Delay Payments.
• Legal or governmental proceedings, labor disputes, or regulatory non-compliance could have a Material Adverse Effect on the Company's financial condition, business, or operations.
• Risk of not preserving Net Operating Losses (NOLs) in accordance with Section 382 of the IRC, which could impact future tax liabilities.

Future Outlook

The Company is committed to filing a preliminary proxy statement within 30 days of closing to seek stockholder approval for the conversion of preferred stock and notes into common stock. It will also file a resale registration statement within 30 days of closing to register the shares issued or issuable. The Company will hold stockholder meetings every 90 days if approval is not obtained. The Notes will bear interest and mature in 2031, and the Company may redeem them under certain conditions after September 1, 2026.

Management Comments

• The Company's decision to enter into these agreements is based on an independent evaluation of the transactions, reflecting a strategic move to secure funding and enhance corporate governance.
• The Company acknowledges the importance of timely SEC filings and maintaining compliance with listing standards to facilitate the resale of securities by investors.

Industry Context

This filing reflects a common strategy for development-stage biotechnology or pharmaceutical companies like Heron Therapeutics to raise capital and manage their debt profiles. Private placements of equity and convertible debt are frequent financing tools in this sector, often accompanied by governance agreements that grant significant investors board representation. The restructuring of existing debt, such as the repurchase of the 2026 convertible notes, is a proactive measure to manage financial obligations and extend maturities, which is a prudent financial practice in capital-intensive industries.

Comparison to Industry Standards

• The 19.99% beneficial ownership limitation for Rubric Capital is a standard 'blocker' provision often seen in private placements to avoid triggering certain change-of-control provisions or shareholder rights plans, aligning with typical investor protections in the biotech sector.
• Granting a board seat to a significant investor like Rubric Capital Management LP is a common practice in private equity or activist investments, providing the investor with direct oversight and influence, comparable to similar arrangements seen with companies like Sarepta Therapeutics or BioMarin Pharmaceutical when they secure strategic investments.
• The terms of the convertible notes, including the 5% cash interest and 7% PIK option, are within the typical range for unsecured convertible debt issued by development-stage biotech companies, which often carry higher interest rates due to perceived risk compared to more mature companies like Amgen or Gilead Sciences.
• The commitment to repurchase or exchange $150 million of existing convertible notes and secure a new $110 million working capital facility with Hercules Capital, Inc. demonstrates a proactive approach to balance sheet management, similar to financial strategies employed by companies such as Acadia Pharmaceuticals or Neurocrine Biosciences to optimize their capital structure.

Management Changes

Corporate Governance

Legal Proceedings

• The Company represents that there are no legal or governmental proceedings pending or threatened that would reasonably be expected to have a Material Adverse Effect on the Company or its Subsidiaries.

Related Party Transactions

• The entire set of transactions (private placement of common and preferred stock, convertible note issuance) constitutes a significant related party transaction between Heron Therapeutics, Inc. and Rubric Capital Management LP (and its funds), as Rubric Capital is becoming a major shareholder and gaining a board seat.

Stakeholder Impact

• Shareholders: Experience dilution from new share issuances but benefit from strengthened financial liquidity, reduced near-term debt obligations, and enhanced corporate governance through investor board representation.
• Employees: Benefit from increased financial stability, which supports ongoing operations and job security.
• Customers: Indirectly benefit from the Company's improved financial health, which supports continued product development and supply.
• Suppliers: Benefit from the Company's enhanced ability to meet its financial obligations.
• Creditors: The new convertible notes are subordinated to existing and future secured debt, and pari passu to unsecured debt, which could affect their recovery priority in certain scenarios. However, the overall debt restructuring aims to improve the Company's financial health.

Next Steps

• The Company will file a preliminary proxy statement within 30 calendar days after the Closing Date to seek stockholder approval for the conversion of Preferred Stock and Notes into Common Stock.
• The Company will call and hold a Stockholder Meeting promptly after filing the proxy statement, and every 90 days thereafter if stockholder approval is not obtained.
• The Company will file a resale registration statement within 30 calendar days after the Closing Date to register the shares issued or issuable in connection with the transactions.
• The Company will enter into an agreement with the Designated Agent to preserve its net operating losses (NOLs) in accordance with IRC Section 382.
• The Company will appoint the Investor Appointee to the Board of Directors upon the closing of the purchase and sale of shares.

Key Dates

Recommendation

The filing indicates a significant capital infusion and a strategic partnership with Rubric Capital, which are positive developments for Heron Therapeutics, a development-stage company. The funding addresses immediate liquidity needs and the board seat for Rubric suggests a more aligned and potentially more effective governance structure. However, the capital raise involves substantial dilution for existing shareholders and adds new debt, albeit with a longer maturity. Given the company's development-stage nature and inherent risks in the biotech sector, a 'hold' recommendation is appropriate. Investors should monitor the company's progress in clinical trials, regulatory approvals, and commercialization efforts, as well as the impact of the new capital structure on future profitability and shareholder value.

Keywords

Heron Therapeutics, Rubric Capital, Capital Raise, Convertible Notes, Preferred Stock, Common Stock, Corporate Governance, Board of Directors, Private Placement, Debt Restructuring, SEC Filing, Biotechnology, Pharmaceuticals, Shareholder Agreement, Investment